Karen Kelly

发表

Computer-Assisted Writing Instruction: A Marriage of Effective Instruction and Technology A Review of Literature

Karen Kelly, K. Kelly, 2002 .

Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens

Robert H. Weiss, Karen Kelly, Sandra L. Taylor, 2017, Bioinform..

Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices

Kyoungmi Kim, Robert H. Weiss, Karen Kelly, 2016, Briefings Bioinform..

Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results.

York E Miller, Tim Byers, Kavita Garg, 2002, Radiology.

Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer

Oliver Fiehn, Kyoungmi Kim, Karen Kelly, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Susanne M Arnold, Mary W Redman, Karen Kelly, 2018, The Lancet. Oncology.

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Mary W Redman, Karen Kelly, J. Crowley, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.

Chun-Ming Tsai, Lucio Crino, Shaf Keshavjee, 2014 .

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Chun-Ming Tsai, Lucio Crinò, Karen Kelly, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

David Cella, Karen Kelly, Roy S Herbst, 2003, JAMA.

Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses

Kyoungmi Kim, Karen Kelly, L Renee Ruhaak, 2013, Analytical and Bioanalytical Chemistry.

Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma

Oliver Fiehn, Kyoungmi Kim, Karen Kelly, 2015, Cancer Prevention Research.

Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.

Oliver Fiehn, Kyoungmi Kim, Harvey I. Pass, 2016, Cancer biomarkers : section A of Disease markers.

N-Glycan profiling of dried blood spots.

Karen Kelly, L Renee Ruhaak, L. R. Ruhaak, 2012, Analytical chemistry.

Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.

Lihong Qi, Patrick A Kupelian, Pin-Chieh Wang, 2017, The Lancet. Oncology.